T. Rowe Price Associates
TLSI icon

T. Rowe Price Associates’s TriSalus Life Sciences TLSI Stock Holding History

T. Rowe Price Associates’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86K Buy
21,294
+6,480
+44% +$31.7K ﹤0.01% 3026
2025
Q4 		$104K Buy
+14,814
New +$83K ﹤0.01% 2939

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

T. Rowe Price Associates's TLSI Position: Q1 2026 in Review

T. Rowe Price Associates increased its TriSalus Life Sciences (TLSI) stake by 44% in Q1 2026, buying an estimated $31.7K and bringing the position to 21,294 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #3026.

T. Rowe Price Associates first reported a position in TLSI in Q4 2025 and has held it in 2 quarters since. The position peaked at $104K in Q4 2025. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • T. Rowe Price Associates held 21,294 shares of TriSalus Life Sciences worth $86K as of Q1 2026.
  • T. Rowe Price Associates bought 6,480 TriSalus Life Sciences shares in Q1 2026, an estimated $31.7K.
  • TriSalus Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3026 holding.
  • T. Rowe Price Associates first reported a position in TriSalus Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • T. Rowe Price Associates's TriSalus Life Sciences position peaked at $104K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.